Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
A Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Southwest Autism Research & Resource Center
-
-
California
-
Los Angeles, California, United States, 90024
- University of California-Los Angeles Neuropsychiatric Institute
-
Sacramento, California, United States, 95817
- M.I.N.D. Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Riley Hospital for Children
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Children's Hospital Boston
-
-
New York
-
Staten Island, New York, United States, 10314
- NYS Institute for Basic Research in Developmental Disabilities
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina Neurosciences Hospital
-
-
Pennsylvania
-
Media, Pennsylvania, United States, 19063
- Suburban Research Associates
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Vanderbilt Kennedy Center
-
-
Texas
-
Houston, Texas, United States, 77090
- Red Oaks Psychiatry Associates, P.A.
-
-
Washington
-
Seattle, Washington, United States, 98101
- Seattle Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects 12 to 40 years of age eventually expanding to 6 years of age
- Molecular documentation of the fragile X mutation.
- Clinical Global Impression - Severity (CGI-S) rating for problem behavior of moderate or higher at screening and at Visit 1
- An Aberrant Behavior Checklist (ABC-C) Irritability Subscale score >12 and at least 3 items on the Irritability Subscale rated at least moderate or above.
- Current treatment with no more than three psychoactive medications, including anti-epileptics.
- Current pharmacological treatment regimen has been stable for at least 4 weeks.
Exclusion Criteria:
- Subjects with a history of seizure disorder who are not currently receiving treatment with antiepileptics.
- Subjects with any condition, including alcohol and drug abuse, which might interfere with the conduct of the study, confound interpretation of the study results, or endanger their own well-being. This includes, but is not limited to impairment of renal function, evidence or history of malignancy or any significant hematological, endocrine, cardiovascular, respiratory, hepatic, or gastrointestinal disease.
- Subjects who plan to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study.
- Subjects who are currently receiving treatment with racemic baclofen.
- Subjects currently treated with vigabatrin or tiagabine.
- Subjects taking another investigational drug currently or within the last 30 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: STX209
STX209 variable dose from 1mg bid to 10mg tid, capsule, oral, 4 weeks
|
Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
Other Names:
|
|
Placebo Comparator: Placebo
variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
|
variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Aberrant Behavior Checklist Irritability Subscore
Time Frame: After 4 weeks of treatment
|
The Aberrant Behavior Checklist-Community Edition (ABC-C) is a 58-item questionnaire composed of five different independent subscales.
The questionnaire is completed by the parent/caregiver and lists aberrant behaviors and asks about the severity of the problem.
ABC-Irritability is one of the subscales and comprises of 15 items.
Minimum score is 0, maximum is 45.
A decreased score indicates few aberrant behaviors and clinical improvement.
The entire ABC-C assessment is administered at baseline and then at the end of each Intervention Period (4 weeks after Baseline).
|
After 4 weeks of treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: James McCracken, MD, University of California, Los Angeles
- Principal Investigator: Elizabeth Berry-Kravis, MD, PhD, Rush University Medical Center
- Principal Investigator: Randi Hagerman, MD, M.I.N.D. Institute
- Principal Investigator: Craig Erikson, MD, Riley Hospital for Children
- Principal Investigator: Bryan King, MD, PhD, Seattle Children's Hospital
- Principal Investigator: Jonathan Picker, MBChB, PhD, Boston Children's Hospital
- Principal Investigator: Linmarie Sikich, MD, University of North Carolina Neurosciences Hospital
- Principal Investigator: Jeremy Veenstra-VanderWeele, MD, Vanderbilt Kennedy Center
- Principal Investigator: Ted Brown, MD, PhD, NYS Institute for Basic Research in Developmental Disabilities
- Principal Investigator: Lawrence Ginsberg, MD, Red Oaks Psychiatry Associates, PA
- Principal Investigator: Raun Melmed, MD, Southwest Autism Research & Resource Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Mental Retardation, X-Linked
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Chromosome Disorders
- Sex Chromosome Disorders
- Syndrome
- Fragile X Syndrome
Other Study ID Numbers
Other Study ID Numbers
- 22001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.